Vivos Inc. has released its quarterly report for the third quarter of 2026, providing insights into its financial performance and ongoing developments. This filing is crucial for understanding the company's position within the surgical and medical instruments sector, especially as it navigates a competitive landscape.
Company Background
Vivos Inc., incorporated in Delaware, operates primarily in the Surgical & Medical Instruments & Apparatus industry (SIC: 3841). The company trades on the OTC exchange under the ticker RDGL. Vivos has been active in the market, with a series of recent filings that reflect its operational activities and strategic initiatives.
What the Filing Says
The 10-Q filing, dated November 12, 2026, details the company's financial results as of September 30, 2026. Specific figures and metrics were not disclosed in the available filing text. However, the report is expected to include information on revenue, expenses, and other key performance indicators that are critical for stakeholders.
Impact
This filing may affect various stakeholders, including investors, analysts, and competitors in the surgical and medical instruments industry. By providing a snapshot of its financial health, Vivos Inc. allows these parties to assess its market position and future prospects.
What's Next
The filing does not specify what actions will follow this report, such as future filings or shareholder meetings. Stakeholders will be watching closely for any subsequent announcements that may provide further clarity on Vivos Inc.'s strategic direction.
Read Next
Madison Technologies reports Q3 results with net loss
Cyberloq Technologies Releases Q3 Results Amid Challenges
Specificity, Inc. Reports Q3 2026 Financial Results
SUNation Energy reports Q3 2026 financial results
Vystar Corp reports on Q3 performance in latest filing
Alpex Acquisition Corp Reports Quarterly Results










